Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orban Biotech has received a $244,000 grant under the US Government's Qualifying Therapeutic Discovery Project (QTDP) program that provides funding support for projects with potential for the prevention, diagnosis and treatment of acute and chronic diseases.
Subscribe to our email newsletter
Orban Biotech said that the QTDP covers funding for a therapeutic insulin B chain vaccine to treat type 1 diabetes mellitus.
The company claims that its insulin B chain vaccine is designed to function by re-establishing self-tolerance towards insulin, thus arresting autoimmune destruction and preserving self-insulin production.
Orban Biotech CEO Tihamer Orban said that they are pleased that Orban Biotech’s therapeutic vaccine has been recognised by this program for its potential to treat type 1 diabetes and other autoimmune disorders.
"Our insulin B chain drug has already completed a Phase I study with promising results and the drug is now poised to move into a Phase II study," Orban said.